ScripHuntington’s disease (HD) has been a notoriously difficult field for drug development but enthusiasm is growing, not least at Skyhawk Therapeutics which has initiated a Phase II/III trial on a potenti
Pink SheetIpsen SA appears to have reset the market for US Food and Drug Administration priority review vouchers after selling its voucher to an unnamed company for $158m. Ipsen received the voucher, which can
ScripIpsen SA has shown itself to be a canny dealmaker over the past few years and its negotiating skills have been shown again with the sale of a priority review voucher (PRV) at well above market rate.
ScripIpsen SA is showing no sign of slowing down on the dealmaking front and has bagged the ex-US licensing rights to Day One Biopharmaceuticals, LLC 's recently approved brain cancer drug, Ojemda. The F